OPTIMUM trial: Ponesimod superior to teriflunomide for relapsing MS

964728

Sumary of OPTIMUM trial: Ponesimod superior to teriflunomide for relapsing MS:

  • The secondary endpoints included changes in Fatigue Symptom and Impact Questionnaire-Relapsing Multiple Sclerosis (FSIQ-RMS), the number of combined active lesions, time to 12-week confirmed disability accumulation and time to 24-week confirmed disability accumulation..
  • .001), and the reduction in 12-week and 24-week confirmed disability accumulation risk estimates was 17% (10.1% vs…

Want to know more click here go to source.

From -
Close
Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages

Site Language


By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close